- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
Francesca Montanari, MD
Biography
Francesca Montanari, MD, is an assistant professor of clinical medicine (hematology) at Yale School of Medicine and sees patients at the Smilow Cancer Center in Greenwich. She is a board-certified hematologist and medical oncologist and provides care to patients with all types of blood diseases, including blood cancers.
Dr. Montanari received her medical degree from the University of Pavia in Italy, where she graduated magna cum laude. She completed a postdoctoral research fellowship at the Herbert Irving Cancer Center at Columbia University, and at the Perlmutter Cancer Center at New York University, focusing on clinical research in lymphoid malignancies.
She then completed both her residency and hematology-oncology fellowship at New York University School of Medicine and was an assistant professor of medicine and experimental therapeutics in the Center for Lymphoid Malignancies at Columbia University, New York Presbyterian Hospital, where she served on the Institutional Review Board Committee and as a director of the Institutional Lymphoma Tumor Board.
Dr. Montanari is a member of the Multidisciplinary T Cell Lymphoma Program and the Lymphoma DART at the Yale Cancer Center. She serves as principal investigator and coinvestigator in several clinical trials.
She is also part of the steering committee of the Lymphoma Research Foundation, New York Lymphoma Rounds.
With more than 15 years of clinical and research experience in lymphomas, Dr Montanari’s interests focus on improving and deepening the knowledge in the less common and less characterized subtypes of lymphomas, on prognostication and on developing therapeutic platforms, lymphoma subtype specific, leveraging developments in biology, biomarkers, and novel agents.
Titles
- Assistant Professor of Medicine (Hematology)
Education & Training
- FellowNew York University (2016)
- ResidentNew York University (2013)
- Post Doctoral Research FellowLaura and Isaac Perlmutter Cancer Center, New York University School of Medicine (2010)
- Post Doctoral Research FellowHerbert Irving Cancer Center, Columbia University (2009)
- FellowUniversity of Pavia Medical Center (2006)
- MDUniversity of Pavia (2002)
Languages Spoken
- English
- Italiano (Italian)
- Español (Spanish)
Additional Information
- AB of Internal Medicine, Medical Oncology (2016)
- AB of Internal Medicine, Hematology (Internal Medicine) (2016)
- Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.
- Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome. Molecular Cancer Therapeutics 2021, 20: 1422-1430. PMID: 34108263, PMCID: PMC8941846, DOI: 10.1158/1535-7163.mct-20-0377.
- Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
- Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor O. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021, 137: 2161-2170. PMID: 33171487, DOI: 10.1182/blood.2020009004.
- Marchi E, Sawas A, Ma H, Scotto L, Montanari F. Innovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma. 2021, 367-377. DOI: 10.1002/9781119671336.ch27.
- Montanari F, Orjuela-Grimm M. Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra. Current Hematologic Malignancy Reports 2021, 16: 52-60. PMID: 33544319, PMCID: PMC8117403, DOI: 10.1007/s11899-021-00606-8.
- Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, Mansukhani MM, Murty VV, Hsiao S, Alobeid B, Bhagat G. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica 2020, 107: 201-210. PMID: 33297669, PMCID: PMC8719101, DOI: 10.3324/haematol.2020.267294.
- Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Matthew M, Loffredo F, Scotto L, Lee H, Kim H, Jacobs A, Rada A, Khan K, Salvia S, Lister J, Benanni N, Francescone M, Zinzani P, Kim W, O'Connor O. Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma. Cancer Research 2020, 80: ct160-ct160. DOI: 10.1158/1538-7445.am2020-ct160.
- Scotto L, Kinahan C, Casadei B, Mangone M, Douglass E, Murty VV, Marchi E, Ma H, George C, Montanari F, Califano A, O'Connor OA. Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Genes Chromosomes And Cancer 2020, 59: 639-651. PMID: 32614991, PMCID: PMC7540375, DOI: 10.1002/gcc.22884.
- Sawas A, Ma H, Kuruvilla J, Lue JK, Deng C, Marchi E, Montanari F, Cheng B, Savage KJ, Villa D, Crump M, Connors JM, O’Connor O. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Leukemia & Lymphoma 2020, 61: 3014-3017. PMID: 32720828, DOI: 10.1080/10428194.2020.1795161.
- Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Scotto L, Jain S, Lister J, Benanni N, Francescone M, Kim W, Zinzani P, O'Connor O. The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Journal Of Clinical Oncology 2020, 38: 8049-8049. DOI: 10.1200/jco.2020.38.15_suppl.8049.
- Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, Connor O, Sawas A. Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances In Hematology 2020, 11: 2040620720947340. PMID: 33062232, PMCID: PMC7534065, DOI: 10.1177/2040620720947340.
- Montanari F, Deng C, Sawas A, Lue J, Marchi E, Radeski D, Cheng B, Bhagat G, O'Connor O. Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood 2019, 134: 2909. DOI: 10.1182/blood-2019-131841.
- O’Connor O, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood 2019, 134: 1395-1405. PMID: 31471376, DOI: 10.1182/blood.2019001285.
- Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Rada A, Malanga M, Francescone M, Soderquist C, Park D, Bhagat G, Sokol L, Shustov A, O'Connor O. TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY. Hematological Oncology 2019, 37: 178-179. DOI: 10.1002/hon.135_2629.
- O'Connor O, Sokol L, Shustov A, Falchi L, Lue J, Montanari F, Amengual J, Sawas A, Deng C, Khan K, Jacobs A, Rada A, Kim H, Soderquist C, Park D, Menezes D. Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response. Journal Of Clinical Oncology 2019, 37: 7565-7565. DOI: 10.1200/jco.2019.37.15_suppl.7565.
- Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Atkins L, Rada A, Serge C, O'Connor O. Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL). Blood 2018, 132: 1002. DOI: 10.1182/blood-2018-99-116605.
- Sawas A, Kuruvilla J, Lue J, Deng C, Amengual J, Montanari F, Savage K, Elgedawe H, Villa D, Crump M, Connors J, O'Connor O. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood 2018, 132: 2907. DOI: 10.1182/blood-2018-99-117251.
- Montanari F, Diefenbach C. Treatment and Prognosis. Molecular Pathology Library 2017, 197-219. DOI: 10.1007/978-3-319-68094-1_9.
- Radeski D, Montanari F, Alobeid B, O'Connor OA, Bhagat G. Post‐transplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger DD & Gross TG. British Journal Of Haematology 2016, 179: 856-857. PMID: 27471184, DOI: 10.1111/bjh.14272.
- Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.
- Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clinical Advances In Hematology And Oncology 2015, 13: 518-24. PMID: 26351815.
- Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.
- Montanari F, Diefenbach C. Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 2014, 9: 284-293. PMID: 24942298, PMCID: PMC4909353, DOI: 10.1007/s11899-014-0220-7.
- Diefenbach C, Sabado R, Brooks C, Baquero-Buitrago J, Cruz C, Vengco I, Montanari F, Marchi E, Scotto L, Cirrito T, Bergstein I, O'Connor O. Hodgkin’s Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,. Blood 2011, 118: 3737. DOI: 10.1182/blood.v118.21.3737.3737.
- Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2010, 10: e43-e46. PMID: 21856550, DOI: 10.3816/clml.2010.n.074.
- Montanari F, Bhagat G, Clark-Garvey S, Seshan V, Zain J, Diefenbach C, Mccormick E, Crook M, Conroy M, O'connor OA. Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders. Leukemia & Lymphoma 2010, 51: 1761-1764. PMID: 20807097, DOI: 10.3109/10428194.2010.500436.
- Montanari F, Bhagat G, Zain J, Seshan V, Magid Diefenbach C, Clark-Garvey S, McCormick E, Crook M, Conroy M, O'Connor O. T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant. Journal Of Clinical Oncology 2010, 28: 8056-8056. DOI: 10.1200/jco.2010.28.15_suppl.8056.
- Montanari F, O'Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology 2010, 41: 1150-1158. PMID: 20381113, DOI: 10.1016/j.humpath.2009.11.016.
- Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals Of Oncology 2008, 19: 1331-1335. PMID: 18344536, DOI: 10.1093/annonc/mdn044.
- Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Montanari F, Rizzi S, Rumi E, Pascutto C, Paulli M, Zuffardi O, Lazzarino M. High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories. Blood 2007, 110: 2620. DOI: 10.1182/blood.v110.11.2620.2620.
- Arcaini L, Burcheri S, Rossi A, Pascutto C, Passamonti F, Brusamolino E, Paulli M, Orlandi E, Buelli M, Viero P, Lucioni M, Montanari F, Merli M, Cortelazzo S, Lazzarino M. Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy. Clinical Cancer Research 2007, 13: 182-186. PMID: 17200353, DOI: 10.1158/1078-0432.ccr-06-0703.
- Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.
- Arcaini L, Paulli M, Burcheri S, Boveri E, Rossi A, Spina M, Passamonti F, Montanari M, Gallamini A, Uziel L, Crugnola M, Montanari F, Pascutto C, Morra E, Lazzarino M. Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour. Blood 2006, 108: 2427. DOI: 10.1182/blood.v108.11.2427.2427.
- Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals Of Oncology 2006, 18: 346-350. PMID: 17071937, DOI: 10.1093/annonc/mdl388.
- Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.
- Arcaini L, Colombo N, Bernasconi P, Calatroni S, Passamonti F, Orlandi E, Bonfichi M, Burcheri S, Della Porta M, Rumi E, Montanari F, Algarotti A, Pascutto C, Lazzarino M. Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia & Lymphoma 2006, 47: 1018-1022. PMID: 16840191, DOI: 10.1080/10428190500467834.
- Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, Della Porta M, Rumi E, Montanari F, Pascutto C, Paulli M, Lazzarino M. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leukemia Research 2005, 30: 277-282. PMID: 16112730, DOI: 10.1016/j.leukres.2005.07.006.
- Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation 2004, 34: 1039-1045. PMID: 15516936, DOI: 10.1038/sj.bmt.1704717.
- Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplantation 2004, 34: 175-179. PMID: 15170171, DOI: 10.1038/sj.bmt.1704551.
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
Biography
Francesca Montanari, MD, is an assistant professor of clinical medicine (hematology) at Yale School of Medicine and sees patients at the Smilow Cancer Center in Greenwich. She is a board-certified hematologist and medical oncologist and provides care to patients with all types of blood diseases, including blood cancers.
Dr. Montanari received her medical degree from the University of Pavia in Italy, where she graduated magna cum laude. She completed a postdoctoral research fellowship at the Herbert Irving Cancer Center at Columbia University, and at the Perlmutter Cancer Center at New York University, focusing on clinical research in lymphoid malignancies.
She then completed both her residency and hematology-oncology fellowship at New York University School of Medicine and was an assistant professor of medicine and experimental therapeutics in the Center for Lymphoid Malignancies at Columbia University, New York Presbyterian Hospital, where she served on the Institutional Review Board Committee and as a director of the Institutional Lymphoma Tumor Board.
Dr. Montanari is a member of the Multidisciplinary T Cell Lymphoma Program and the Lymphoma DART at the Yale Cancer Center. She serves as principal investigator and coinvestigator in several clinical trials.
She is also part of the steering committee of the Lymphoma Research Foundation, New York Lymphoma Rounds.
With more than 15 years of clinical and research experience in lymphomas, Dr Montanari’s interests focus on improving and deepening the knowledge in the less common and less characterized subtypes of lymphomas, on prognostication and on developing therapeutic platforms, lymphoma subtype specific, leveraging developments in biology, biomarkers, and novel agents.
Titles
- Assistant Professor of Medicine (Hematology)
Education & Training
- FellowNew York University (2016)
- ResidentNew York University (2013)
- Post Doctoral Research FellowLaura and Isaac Perlmutter Cancer Center, New York University School of Medicine (2010)
- Post Doctoral Research FellowHerbert Irving Cancer Center, Columbia University (2009)
- FellowUniversity of Pavia Medical Center (2006)
- MDUniversity of Pavia (2002)
Languages Spoken
- English
- Italiano (Italian)
- Español (Spanish)
Additional Information
- AB of Internal Medicine, Medical Oncology (2016)
- AB of Internal Medicine, Hematology (Internal Medicine) (2016)
- Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.
- Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome. Molecular Cancer Therapeutics 2021, 20: 1422-1430. PMID: 34108263, PMCID: PMC8941846, DOI: 10.1158/1535-7163.mct-20-0377.
- Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
- Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor O. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021, 137: 2161-2170. PMID: 33171487, DOI: 10.1182/blood.2020009004.
- Marchi E, Sawas A, Ma H, Scotto L, Montanari F. Innovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma. 2021, 367-377. DOI: 10.1002/9781119671336.ch27.
- Montanari F, Orjuela-Grimm M. Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra. Current Hematologic Malignancy Reports 2021, 16: 52-60. PMID: 33544319, PMCID: PMC8117403, DOI: 10.1007/s11899-021-00606-8.
- Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, Mansukhani MM, Murty VV, Hsiao S, Alobeid B, Bhagat G. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica 2020, 107: 201-210. PMID: 33297669, PMCID: PMC8719101, DOI: 10.3324/haematol.2020.267294.
- Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Matthew M, Loffredo F, Scotto L, Lee H, Kim H, Jacobs A, Rada A, Khan K, Salvia S, Lister J, Benanni N, Francescone M, Zinzani P, Kim W, O'Connor O. Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma. Cancer Research 2020, 80: ct160-ct160. DOI: 10.1158/1538-7445.am2020-ct160.
- Scotto L, Kinahan C, Casadei B, Mangone M, Douglass E, Murty VV, Marchi E, Ma H, George C, Montanari F, Califano A, O'Connor OA. Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Genes Chromosomes And Cancer 2020, 59: 639-651. PMID: 32614991, PMCID: PMC7540375, DOI: 10.1002/gcc.22884.
- Sawas A, Ma H, Kuruvilla J, Lue JK, Deng C, Marchi E, Montanari F, Cheng B, Savage KJ, Villa D, Crump M, Connors JM, O’Connor O. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Leukemia & Lymphoma 2020, 61: 3014-3017. PMID: 32720828, DOI: 10.1080/10428194.2020.1795161.
- Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Scotto L, Jain S, Lister J, Benanni N, Francescone M, Kim W, Zinzani P, O'Connor O. The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Journal Of Clinical Oncology 2020, 38: 8049-8049. DOI: 10.1200/jco.2020.38.15_suppl.8049.
- Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, Connor O, Sawas A. Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances In Hematology 2020, 11: 2040620720947340. PMID: 33062232, PMCID: PMC7534065, DOI: 10.1177/2040620720947340.
- Montanari F, Deng C, Sawas A, Lue J, Marchi E, Radeski D, Cheng B, Bhagat G, O'Connor O. Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood 2019, 134: 2909. DOI: 10.1182/blood-2019-131841.
- O’Connor O, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood 2019, 134: 1395-1405. PMID: 31471376, DOI: 10.1182/blood.2019001285.
- Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Rada A, Malanga M, Francescone M, Soderquist C, Park D, Bhagat G, Sokol L, Shustov A, O'Connor O. TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY. Hematological Oncology 2019, 37: 178-179. DOI: 10.1002/hon.135_2629.
- O'Connor O, Sokol L, Shustov A, Falchi L, Lue J, Montanari F, Amengual J, Sawas A, Deng C, Khan K, Jacobs A, Rada A, Kim H, Soderquist C, Park D, Menezes D. Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response. Journal Of Clinical Oncology 2019, 37: 7565-7565. DOI: 10.1200/jco.2019.37.15_suppl.7565.
- Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Atkins L, Rada A, Serge C, O'Connor O. Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL). Blood 2018, 132: 1002. DOI: 10.1182/blood-2018-99-116605.
- Sawas A, Kuruvilla J, Lue J, Deng C, Amengual J, Montanari F, Savage K, Elgedawe H, Villa D, Crump M, Connors J, O'Connor O. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood 2018, 132: 2907. DOI: 10.1182/blood-2018-99-117251.
- Montanari F, Diefenbach C. Treatment and Prognosis. Molecular Pathology Library 2017, 197-219. DOI: 10.1007/978-3-319-68094-1_9.
- Radeski D, Montanari F, Alobeid B, O'Connor OA, Bhagat G. Post‐transplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger DD & Gross TG. British Journal Of Haematology 2016, 179: 856-857. PMID: 27471184, DOI: 10.1111/bjh.14272.
- Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.
- Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clinical Advances In Hematology And Oncology 2015, 13: 518-24. PMID: 26351815.
- Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.
- Montanari F, Diefenbach C. Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 2014, 9: 284-293. PMID: 24942298, PMCID: PMC4909353, DOI: 10.1007/s11899-014-0220-7.
- Diefenbach C, Sabado R, Brooks C, Baquero-Buitrago J, Cruz C, Vengco I, Montanari F, Marchi E, Scotto L, Cirrito T, Bergstein I, O'Connor O. Hodgkin’s Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,. Blood 2011, 118: 3737. DOI: 10.1182/blood.v118.21.3737.3737.
- Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2010, 10: e43-e46. PMID: 21856550, DOI: 10.3816/clml.2010.n.074.
- Montanari F, Bhagat G, Clark-Garvey S, Seshan V, Zain J, Diefenbach C, Mccormick E, Crook M, Conroy M, O'connor OA. Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders. Leukemia & Lymphoma 2010, 51: 1761-1764. PMID: 20807097, DOI: 10.3109/10428194.2010.500436.
- Montanari F, Bhagat G, Zain J, Seshan V, Magid Diefenbach C, Clark-Garvey S, McCormick E, Crook M, Conroy M, O'Connor O. T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant. Journal Of Clinical Oncology 2010, 28: 8056-8056. DOI: 10.1200/jco.2010.28.15_suppl.8056.
- Montanari F, O'Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology 2010, 41: 1150-1158. PMID: 20381113, DOI: 10.1016/j.humpath.2009.11.016.
- Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals Of Oncology 2008, 19: 1331-1335. PMID: 18344536, DOI: 10.1093/annonc/mdn044.
- Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Montanari F, Rizzi S, Rumi E, Pascutto C, Paulli M, Zuffardi O, Lazzarino M. High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories. Blood 2007, 110: 2620. DOI: 10.1182/blood.v110.11.2620.2620.
- Arcaini L, Burcheri S, Rossi A, Pascutto C, Passamonti F, Brusamolino E, Paulli M, Orlandi E, Buelli M, Viero P, Lucioni M, Montanari F, Merli M, Cortelazzo S, Lazzarino M. Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy. Clinical Cancer Research 2007, 13: 182-186. PMID: 17200353, DOI: 10.1158/1078-0432.ccr-06-0703.
- Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.
- Arcaini L, Paulli M, Burcheri S, Boveri E, Rossi A, Spina M, Passamonti F, Montanari M, Gallamini A, Uziel L, Crugnola M, Montanari F, Pascutto C, Morra E, Lazzarino M. Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour. Blood 2006, 108: 2427. DOI: 10.1182/blood.v108.11.2427.2427.
- Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals Of Oncology 2006, 18: 346-350. PMID: 17071937, DOI: 10.1093/annonc/mdl388.
- Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.
- Arcaini L, Colombo N, Bernasconi P, Calatroni S, Passamonti F, Orlandi E, Bonfichi M, Burcheri S, Della Porta M, Rumi E, Montanari F, Algarotti A, Pascutto C, Lazzarino M. Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia & Lymphoma 2006, 47: 1018-1022. PMID: 16840191, DOI: 10.1080/10428190500467834.
- Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, Della Porta M, Rumi E, Montanari F, Pascutto C, Paulli M, Lazzarino M. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leukemia Research 2005, 30: 277-282. PMID: 16112730, DOI: 10.1016/j.leukres.2005.07.006.
- Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation 2004, 34: 1039-1045. PMID: 15516936, DOI: 10.1038/sj.bmt.1704717.
- Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplantation 2004, 34: 175-179. PMID: 15170171, DOI: 10.1038/sj.bmt.1704551.
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830